India, April 5 -- Anavex Life Sciences Corp. (AVXL) announced that more than three years of continuous treatment with blarcamesine (ANAVEX 2-73) significantly improved clinical decline, demonstrating sustained and meaningful benefits for early Alzheimer's disease patients, according to results from the Phase IIb/III open-label extension trial.
The company noted that continued blarcamesine treatment up to four years demonstrated good comparative safety profile and no associated neuroimaging adverse events (no potentially fatal brain bleeding or brain swelling). There were no deaths related to the study drug.
The ATTENTION-AD (ANAVEX2-73-AD-EP-004) trial followed the 48-week ANAVEX2-73-AD-004 double-blind (DB) clinical trial, lasting up to ...